BETHESDA, Md., Dec. 7, 2016 /PRNewswire-USNewswire/ -- The Parenteral Drug Association (PDA) today announced the results of its Board of Directors Election for the term beginning January 2017.
Barbara Allen, PhD, Sr. Director, Global Quality Systems, Eli Lilly & Company, and Ghada Haddad, Director, Global Quality Risk Management Center of Excellence, Merck, were elected to the Board for the first time. Joyce Bloomfield and Véronique Davoust, PharmD, Senior Manager, Global Quality Intelligence, Pfizer, were reelected.
PDA thanks outgoing Directors Glenn Wright, Senior Director, Project Management TS/MS, Eli Lilly & Company, and John Shabushnig, PhD, Principal Consultant, Insight Pharma Consulting for their service to the organization.
About PDA – Connecting People, Science and Regulation®
The Parenteral Drug Association (PDA) is the leading global provider of science, technology and regulatory information and education for the pharmaceutical and biopharmaceutical community. Founded in 1946 as a nonprofit organization, PDA is committed to developing scientifically sound, practical technical information and resources to advance science and regulation through the expertise of its 10,000 members worldwide. Go to http://www.pda.org/footer/about-pda to learn more.
Media Inquiries: Walt Morris, 301-656-5900, x. 148; email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pda-announces-results-of-board-of-directors-election-300374566.html
SOURCE Parenteral Drug Association